News

News

FDA Expands Ivosidenib’s Indication to Newly Diagnosed AML

On May 2, the U.S. Food and Drug Administration (FDA) approved an expanded indication for the IDH1 inhibitor ivosidenib to include the treatment of...

Citing Theft of Research for China, MD Anderson Dismisses Three Scientists

Houston’s MD Anderson Cancer Center dismissed three of five researchers whom federal authorities alleged were involved the theft of American research for China. The ousted...

Medicare Payments for CAR T-Cell Therapy May Be on the Rise

Medicare beneficiaries with relapsed or refractory leukemia and lymphoma may soon have another treatment option. At least, that’s the hope of officials at the...

Email Breach at EmCare Exposes Personal Data of 31,000 Patients

An email breach at EmCare, a Florida-based physician staffing company, has exposed personal data from 60,000 people, including 31,000 patients. Information exposed in the mid-February...

Europe Poised to Approve Hydroxyurea for Sickle Cell Disease

Europe’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Medicines Agency (EMA) grant marketing authorization to hydroxyurea for the...

FDA Names Elizabeth Jungman Head of Regulatory Policy

The U.S. Food and Drug Administration (FDA) has selected Elizabeth Jungman, JD, MPH, to serve as the head of the FDA’s Office of Regulatory...

Patients With Advanced Cancer Often Choose Aggressive Treatments, Despite Questionable Benefits

Even with terminal diagnoses, up to 25 percent of patients with advanced cancer who are given less than one month to live resort to...

Five Decades of Experience With MPNs: Characterizing Survival and Outcomes

A report based on data from more than 3,000 patients with myeloproliferative neoplasms (MPNs) evaluated at the Mayo Clinic in Rochester, Minnesota, over 50...
WIB_icon

Evaluating Thalidomide-Cyclophosphamide-Prednisone for Idiopathic Multicentric Castleman Disease

An oral combination of thalidomide, cyclophosphamide, and prednisone (TCP) induced durable tumor and symptomatic response rates in nearly half of patients with newly diagnosed...

FDA Halts Trials of Venetoclax for Myeloma

The U.S. Food and Drug Administration (FDA) has issued a warning to health-care professionals and clinical investigators about the risks associated with the investigational...
Advertisement

Current Issue

June 2019, Volume 5, Issue 7

This issue features a debate about new treatment options for beta-thalassemia, a look at what’s driving skyrocketing drug prices in myeloma, and more.